Clinical Trials
28 trialsS0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Fox Chase Cancer Center
Study of Arsenic Trioxide in Small Cell Lung Cancer
Emory University
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Case Comprehensive Cancer Center
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Albert Einstein College of Medicine
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
The University of Texas Health Science Center at San Antonio
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
University of Pittsburgh
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Memorial Sloan Kettering Cancer Center
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
The Cleveland Clinic
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
University of Chicago
Arsenic Trioxide in Treating Men With Germ Cell Cancer
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Arsenic Trioxide in Treating Patients With Urothelial Cancer
National Cancer Institute (NCI)
Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The University of Texas Medical Branch, Galveston
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
Northwestern University
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
New Mexico Cancer Research Alliance
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SCRI Development Innovations, LLC
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Tehran University of Medical Sciences
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
SCRI Development Innovations, LLC